Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Lumen Technologies Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Lumen Technologies Inc trades at $6.56 (market cap $6.64B). The key difference: Lumen Technologies Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | LUMN | |
|---|---|---|
Market Cap | $4.49B | $6.64B |
Sector | Health | Media |
52-Week High | $28.06 | $11.83 |
52-Week Low | $20.06 | $3.70 |
Enterprise Value | $3.69B | $18.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
LUMN trades at $6.44, up 0.16% on the day, with a bearish technical signal but bullish oscillators. The company reported a net loss of $1.74B in 2025, though it beat EPS estimates in two of the last three quarters. Recent news highlights the completion of the Alkira acquisition, aimed at boosting its AI-era networking capabilities. Revenue has declined from $17.5B in 2022 to $12.4B in 2025, with a negative net income margin of -14.34%.
The outlook remains challenging due to persistent losses and high debt, but strategic acquisitions and a 15% forward free cash flow yield offer potential upside. Risks include execution hurdles in integrating acquisitions and intense telecom competition. Analyst consensus is a Hold with a $8.25 price target, suggesting cautious optimism amid fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
